Corporate
Dec. 7, 2013
Cooley advises San Diego anti-bacterial drugmaker in $140M sale
The Rempex Pharmaceuticals acquisition is expected to help The Medicines Co. fill a gap in its offerings pipeline and complement the company's Gram-positive product line.
Daily Journal Staff Writer
Cooley LLP represented San Diego-based drugmaker Rempex Pharmaceuticals Inc. in its sale to The Medicines Co. for $140 million upfront and up to $334 million more if certain milestones are met.
Rempex develops drugs targeting multidrug-resistant, Gram-negative bacterial infections. Gram-negative bacteria, after Danish bacteriologist Hans Christian Gram, are the more antibiotic-resistant of two clas...
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In